Does molecular monitoring matter in early-stage breast cancer?

Tilak K Sundaresan¹, Daniel A Haber²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. dhaber@mgh.harvard.edu.

PMID: 26311727
DOI: 10.1126/scitranslmed.aac9445

Comment

Does molecular monitoring matter in early-stage breast cancer?

Tilak K Sundaresan et al. Sci Transl Med. 2015.

. 2015 Aug 26;7(302):302fs35.

doi: 10.1126/scitranslmed.aac9445.

Authors

Tilak K Sundaresan¹, Daniel A Haber²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. dhaber@mgh.harvard.edu.

PMID: 26311727
DOI: 10.1126/scitranslmed.aac9445

Abstract

Serial monitoring of circulating tumor DNA predicts recurrence after treatment for localized breast cancer (Garcia-Murillas et al., this issue).

PubMed Disclaimer

Comment on

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Garcia-Murillas I, et al. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021. Sci Transl Med. 2015. PMID: 26311728

Cited by

Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
Zhang X, Ju S, Wang X, Cong H. Zhang X, et al. Clin Exp Med. 2019 Aug;19(3):271-279. doi: 10.1007/s10238-019-00563-w. Epub 2019 Jun 12. Clin Exp Med. 2019. PMID: 31190187 Review.
The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC.
Zhao X, Dai F, Mei L, Huang D, Shen X, Zhang H, She X, Ma Z. Zhao X, et al. Front Oncol. 2021 Jul 16;11:671963. doi: 10.3389/fonc.2021.671963. eCollection 2021. Front Oncol. 2021. PMID: 34336662 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Does molecular monitoring matter in early-stage breast cancer?

Affiliations

Does molecular monitoring matter in early-stage breast cancer?

Authors

Affiliations

Abstract

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical